CYP19A1 and breast carcinoma: Although few studies have been conducted on the genome encoding aromatase expression, it has been observed that, in breast cancer, the aromatase enzyme has single nucleotide polymorphisms (SNPs) that could interfere with the efficacy of anastrozole [58].